Medical device companies developing products for drug-treated populations must understand the clinical, health economic, and marketing challenges that manifest from this convergence, or risk their…
How Are Payer Policies and Physician Preferences Shaping the Prescribing Landscape? The European oral anticoagulation market has undergone a dramatic expansion in the treatment armamentarium in…
Last Updated 22 December 2014 Atrial fibrillation (AF) is the most common cardiac arrhythmia encountered in clinical practice. AF is a major cause of morbidity and mortality and is therefore a…
For the estimated 4.6 million people in the United States who suffer from atrial fibrillation (AF), several treatment approaches and a wide range of pharmacological treatment options are available…
The launch of novel oral anticoagulants (NOACs), such as Bayer/Janssen’s Xarelto, Bristol-Myers Squibb/Pfizer’s Eliquis/Elicuis, and Boehringer Ingelheim’s Pradaxa/Pradaxar, in Brazil and…
Warfarin has been the mainstay of anticoagulation therapy for the past several decades, but difficulties associated with its use and the clinical management of patients have prompted the…
Accountable care organizations (ACOs), in which providers are held accountable for the costs of treating a payer’s patent population, will become more the rule than the exception in a year, as…
Venous thromboembolism (VTE) is a potentially fatal cardiovascular condition characterized by the development of a thrombus in the vasculature. Treatment options for VTE have been largely limited…